89BIO INC. - COMMON STOCK

89bio to Participate in Upcoming Investor Conferences

29 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 أغسطس 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Appoints Francis Sarena as Chief Operating Officer

07 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

05 أغسطس 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

05 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 يوليو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 يونيو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

22 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

14 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio to Participate in the BofA Securities 2024 Health Care Conference

08 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

02 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

17 أبريل 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 أبريل 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

27 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

12 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08 مارس 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio to Participate in the Leerink Partners Global Biopharma Conference

05 مارس 2024 15:05:00 بحسب Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

29 فبراير 2024 15:05:00 بحسب Nasdaq GlobeNewswire